Risperidone reduction of amphetamine-induced self-injurious behavior in mice

George Wagner, Nicole Avena, Taizo Kita, Toshikatsu Nakashima, Hans Fisher, Alycia K. Halladay

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The behavioral and neurochemical effects of high doses of amphetamine administered to BALB/c mice were examined in the presence and absence of co-administered haloperidol (a D2 antagonist), SCH 23390 (a D 1 antagonist) and risperidone (a mixed 5-HT2/D 2 antagonist). It was observed that mice displayed a dose-dependent increase in stereotypic behavior, oral dyskinesia, and self-injurious behavior (SIB) in response to amphetamine treatment. Furthermore, agents that blocked the SIB reversed the amphetamine-induced release of serotonin. This effect was unrelated to hyperthermia or non-specific sedation (as assessed by measurement of motor activity). These data are interpreted in the context of the underlying basis of murine SIB involving both dopaminergic and serotonergic activation and demonstrate the efficacy of risperidone in treating these behaviors.

Original languageEnglish (US)
Pages (from-to)700-708
Number of pages9
JournalNeuropharmacology
Volume46
Issue number5
DOIs
StatePublished - Apr 1 2004

Fingerprint

Self-Injurious Behavior
Risperidone
Amphetamine
Movement Disorders
Haloperidol
Serotonin
Motor Activity
Fever

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cellular and Molecular Neuroscience

Keywords

  • Autism
  • Dopamine
  • Mice
  • Risperidone
  • Self-injurious behavior
  • Serotonin

Cite this

Wagner, George ; Avena, Nicole ; Kita, Taizo ; Nakashima, Toshikatsu ; Fisher, Hans ; Halladay, Alycia K. / Risperidone reduction of amphetamine-induced self-injurious behavior in mice. In: Neuropharmacology. 2004 ; Vol. 46, No. 5. pp. 700-708.
@article{abbffef41b2c43e39359c1464280186f,
title = "Risperidone reduction of amphetamine-induced self-injurious behavior in mice",
abstract = "The behavioral and neurochemical effects of high doses of amphetamine administered to BALB/c mice were examined in the presence and absence of co-administered haloperidol (a D2 antagonist), SCH 23390 (a D 1 antagonist) and risperidone (a mixed 5-HT2/D 2 antagonist). It was observed that mice displayed a dose-dependent increase in stereotypic behavior, oral dyskinesia, and self-injurious behavior (SIB) in response to amphetamine treatment. Furthermore, agents that blocked the SIB reversed the amphetamine-induced release of serotonin. This effect was unrelated to hyperthermia or non-specific sedation (as assessed by measurement of motor activity). These data are interpreted in the context of the underlying basis of murine SIB involving both dopaminergic and serotonergic activation and demonstrate the efficacy of risperidone in treating these behaviors.",
keywords = "Autism, Dopamine, Mice, Risperidone, Self-injurious behavior, Serotonin",
author = "George Wagner and Nicole Avena and Taizo Kita and Toshikatsu Nakashima and Hans Fisher and Halladay, {Alycia K.}",
year = "2004",
month = "4",
day = "1",
doi = "10.1016/j.neuropharm.2003.11.009",
language = "English (US)",
volume = "46",
pages = "700--708",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "5",

}

Wagner, G, Avena, N, Kita, T, Nakashima, T, Fisher, H & Halladay, AK 2004, 'Risperidone reduction of amphetamine-induced self-injurious behavior in mice', Neuropharmacology, vol. 46, no. 5, pp. 700-708. https://doi.org/10.1016/j.neuropharm.2003.11.009

Risperidone reduction of amphetamine-induced self-injurious behavior in mice. / Wagner, George; Avena, Nicole; Kita, Taizo; Nakashima, Toshikatsu; Fisher, Hans; Halladay, Alycia K.

In: Neuropharmacology, Vol. 46, No. 5, 01.04.2004, p. 700-708.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Risperidone reduction of amphetamine-induced self-injurious behavior in mice

AU - Wagner, George

AU - Avena, Nicole

AU - Kita, Taizo

AU - Nakashima, Toshikatsu

AU - Fisher, Hans

AU - Halladay, Alycia K.

PY - 2004/4/1

Y1 - 2004/4/1

N2 - The behavioral and neurochemical effects of high doses of amphetamine administered to BALB/c mice were examined in the presence and absence of co-administered haloperidol (a D2 antagonist), SCH 23390 (a D 1 antagonist) and risperidone (a mixed 5-HT2/D 2 antagonist). It was observed that mice displayed a dose-dependent increase in stereotypic behavior, oral dyskinesia, and self-injurious behavior (SIB) in response to amphetamine treatment. Furthermore, agents that blocked the SIB reversed the amphetamine-induced release of serotonin. This effect was unrelated to hyperthermia or non-specific sedation (as assessed by measurement of motor activity). These data are interpreted in the context of the underlying basis of murine SIB involving both dopaminergic and serotonergic activation and demonstrate the efficacy of risperidone in treating these behaviors.

AB - The behavioral and neurochemical effects of high doses of amphetamine administered to BALB/c mice were examined in the presence and absence of co-administered haloperidol (a D2 antagonist), SCH 23390 (a D 1 antagonist) and risperidone (a mixed 5-HT2/D 2 antagonist). It was observed that mice displayed a dose-dependent increase in stereotypic behavior, oral dyskinesia, and self-injurious behavior (SIB) in response to amphetamine treatment. Furthermore, agents that blocked the SIB reversed the amphetamine-induced release of serotonin. This effect was unrelated to hyperthermia or non-specific sedation (as assessed by measurement of motor activity). These data are interpreted in the context of the underlying basis of murine SIB involving both dopaminergic and serotonergic activation and demonstrate the efficacy of risperidone in treating these behaviors.

KW - Autism

KW - Dopamine

KW - Mice

KW - Risperidone

KW - Self-injurious behavior

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=1442348877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1442348877&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2003.11.009

DO - 10.1016/j.neuropharm.2003.11.009

M3 - Article

C2 - 14996547

AN - SCOPUS:1442348877

VL - 46

SP - 700

EP - 708

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 5

ER -